### CLINICAL MANIFESTATIONS
**Neuropsychiatry And Behavioral Neurology, Neuropsychology**

### DRUG DEVELOPMENT
**Human, Nonhuman**

Sessions are listed in Central Daylight Time (North America). Schedule is current at time of posting. Content is listed as submitted. Session chairs are listed in bold.

#### PLENARY SESSIONS
Learn about the state of the field from leading experts.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| 10 a.m. | Mechanisms Of Neurovascular Dysfunction And Interaction With Alzheimer's Disease Pathology | Costantino Iadecola, M.D.  
Early-Onset Alzheimer's Disease  
Nick Fox, M.D. |

#### LIVE SESSIONS
Attend sessions on clinical manifestations and drug development and engage in live discussion.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 a.m.</td>
<td>Developing Topic Session: Developments In Clinical Trials And Cognitive Assessment</td>
<td>Hugo Geerts, Cedric O’Gorman, Samantha Budd Haeberlein, Jordi A. Matias-Guiu, Francesca K. Cormack, Olivia L. Hampton</td>
</tr>
<tr>
<td>7 a.m.</td>
<td>Using Digital Technology To Drive Clinical Innovation In Brain-Behavior Relationships: A New Era In Neuropsychology</td>
<td>Alexandra Atkins, Kathleen A. Welsh-Bohmer, David J. Libon, Kathryn V. Papp, Jason Hassenstab, Rhoda Au</td>
</tr>
<tr>
<td>7 a.m.</td>
<td>Neuropsychiatric Symptoms As A Treatment Target: Recent Advances By The ISTAART Neuropsychiatric Symptoms Professional Interest Area</td>
<td>Jennifer R. Gatchel, Corinne E. Fischer, Amer M. Burhan, Moyra E. Mortby</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>Alzheimer’s Prevention Initiative (API) Generation Program: Baseline Characteristics And Umibecestat Results During Treatment And Follow-Up</td>
<td>Florence Pasquier, Thomas Obisesan, Pierre N. Tariot, Marie-Laure Rouzade-Dominguez, Ana Graf, Eric M. Reiman</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>Neuropsychiatry And Behavioral Neurology: DLB and FTD - Clinical Manifestations</td>
<td>Wiesje Van Der Flier, Valérie Godefroy, Parichita Choudhury, Frédéric Blanc, Bradley F. Boeve, Atri Chatterjee, Marleen Van De Beek</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>Using Technology To Improve Access To Cognitive Assessments And Interventions</td>
<td>Maureen Schmitter-Edgecombe, Rema Raman, Paul T. Maruff, Jesus Favela, Simon L. Collinson</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Methodologic Development And Advancements In Clinical Trials Targeting Vascular Cognitive Impairment And Dementia (VCID)</td>
<td>Gregory Jicha, Atticus Hainsworth, Lon Schneider, Roderick A. Corriveau, Deborah R. Gustafson, Ruth Peters</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Repurposing Drugs Targeting Glia And Inflammatory Mechanisms</td>
<td>Linda Van Eldik, Cynthia Lemere, Malu Gamez Tansey, Howard M. Fillit, Knut Biber, Clive Ballard</td>
</tr>
</tbody>
</table>

Continuing Education is available for select sessions — learn more.
Wednesday, July 29
Clinical Manifestations and Drug Development

LIVE SESSIONS, CONTINUED

11:30 a.m. The Transitional Stage 2 Of Alzheimer’s Disease – Clinical Features, Biomarkers And Longitudinal Course
Rebecca Amariglio, Ronald C. Petersen, Wiesje Van Der Flier, Frank Jessen

1 p.m. Biomarkers And Early Diagnosis Of DLB: New Findings
Dag Aarsland, Bradley Boeve, James B. Leverenz, Kejal Kantarci, Laura Bonanni, Doug R. Galasko

1 p.m. Results Of The DIAN-TU Prevention Trial Of Solanezumab And Gantenerumab In Dominantly Inherited Alzheimer’s Disease (Please view the accompanying on-demand sessions in advance)
Randall Bateman, Laurie Ryan, Maria C. Carrillo, Geoffrey Kerchner, Martin Farlow, Stephen Salloway, Roy Yaari

POSTER PRESENTATIONS

Explore the latest clinical manifestations and drug development research with posters from across the world. Leave comments for authors around the clock. Posters on this topic will be available on Tuesday, July 28, at 5 p.m.

ON-DEMAND SESSIONS AND Q&A

View the on-demand sessions and then join experts and peers for live discussions of select content in dedicated chat rooms. We recommend viewing on-demand sessions in advance — the following content will be available on Tuesday, July 28, at 5 p.m.

ON-DEMAND SESSIONS

» Neuropsychiatry And Behavioral Neurology: Neuropsychiatric Symptoms In MCI And Dementia
Janina Krell-Roesch, Yu-Yuan Huang, Patrizia Vannini, Russell J. Chander, Fennie Wong, Leah K. Forsberg

» Neuropsychology: Neuropsychological Correlates Of Pathology: Novel And Standard Cognitive Markers Of Disease
Merilee Teylan, Bibek Gyanwali, Yen Ying Lim, Rebecca Singleton

» Clinical Manifestations: Update On Pharmacologic And Nonpharmacologic Interventions
Walter Swardfager, Maria Eriksdotter, Che-Yuan Wu, Roger Alan Bullock, Juan Li, Frank Ho-Yin Lai, Suzanne B. Hendrix

» Neuropsychology: Awareness Of Cognitive Capacities And Subjective Cognitive Decline
Katya T. Numbers, Igor Koval, Mercè Boada, Patricia Diaz-Galvan, Federica Cacciamani

» Nonhuman: Preclinical Immunotherapeutic Studies
Johanne Kaplan, Chin-Yin Tai, Fernando Goni, Guus Scheefhals, Rebecca M. Nisbet, Maria Clara Selles

» Drug Development: Preclinical Small Molecule Drug Discovery
James G. Moe, Tahir Ali, Ingrid L. Kwee, Satoshi Saito, Christopher M. Norris, Amira Latif-Hernandez

» Neuropsychiatry And Behavioral Neurology: The Neuropsychiatry Of Subjective Cognitive Disorder And Prodromal Alzheimer’s Disease
Qing Wang, Harriet Demnitz-King, Krister Håkansson, Tau Ming Liew, Gonzalo Sánchez-Benavides, Roos J. Jutten

» Examining Subjective Cognitive Decline In Diverse, Ethnoracial Populations
Rebecca Amariglio, Yakeel Quiroz, Timothy M. Hughes, Arline Faustin, Mindy J. Katz, Dix U. Meiberth

» Nonhuman: Preclinical Studies On APOE And Neuroinflammation
Boris Kantor, Maria Sebastian, Chad Smith, Lauren H. Fairley, Alexey Kostikov

Q&A TIME

6:30 a.m. 6:30 a.m. 7 a.m. 7:30 a.m. 8 a.m. 8 a.m. 8:30 a.m. 8:30 a.m. 9 a.m. 9 a.m.
<table>
<thead>
<tr>
<th>ON-DEMAND SESSIONS</th>
<th>Q&amp;A TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Examinining Subjective Cognitive Decline Through An Interdisciplinary Lens</strong>  &lt;br&gt;Stephanie Cosentino, Jacqueline Mogle, Katherine A. Gifford, Silvia Chapman, Serena Sabatini</td>
<td>9:30 a.m.</td>
</tr>
<tr>
<td><strong>The Conduct of Clinical Investigations In The Down Syndrome Population</strong>  &lt;br&gt;James A. Hendrix, Juan Fortea, Andre Strydom, Joanne M. Bell</td>
<td>9:30 a.m.</td>
</tr>
<tr>
<td><strong>Drug Development: Clinical Trial Design And Implementation</strong>  &lt;br&gt;Trisha L. Walsh, Michael C. Donohue, Emily A. Largent, Amanda G. Smith, Paul S. Aisen, John Didsbury</td>
<td>11 a.m.</td>
</tr>
<tr>
<td><strong>Neuropsychiatry And Behavioral Neurology: Novel Risk Factors And Novel Approaches To Risk In Dementia</strong>  &lt;br&gt;Magda Bucholc, Miranka Wirth, Chinedu T. Udeh-Momoh, Manuel Montero-Odasso, Alicia S. Parker, Zachary A. Miller</td>
<td>11 a.m.</td>
</tr>
<tr>
<td><strong>An Update On The Pathological, Imaging And Clinical Features Underlying Heterogeneity Across Individuals With Alzheimer’s Disease</strong>  &lt;br&gt;Rik Ossenkoppele, Femke Bouwman, Paul K. Crane, David T. Jones, Renaud La Joie, Baayla D.C. Boon</td>
<td>11:30 a.m.</td>
</tr>
<tr>
<td><strong>Human: Improving Clinical Trial Methodology</strong>  &lt;br&gt;David Gordon, Samuel P. Dickson, Andrea Z. Lacroix, Stina Saunders, Elena Ratti, Ali Ezzati</td>
<td>11:30 a.m.</td>
</tr>
<tr>
<td><strong>Neuropsychology: Cognitive And Functional Assessment In Diverse Populations</strong>  &lt;br&gt;Golden Mwakibo Masika, Rachel A. Whitmer, Monica Rivera Mindt, Richard Gershon, Maria M. M. Corrada</td>
<td>Noon</td>
</tr>
<tr>
<td><strong>Tau Therapies: From Mouse To Molecule</strong>  &lt;br&gt;Jeffrey L. Cummings, Nicolas R. Barthelemy, Adam L. Boxer</td>
<td>Noon</td>
</tr>
<tr>
<td><strong>Human: Putative Therapeutic Results For Alzheimer’s And Related Dementias</strong>  &lt;br&gt;Glen Wunderlich, Erin P. Foff, Robert Paul, Michael S. Rafii, Jennifer L. Stacey, Ihab Hajjar</td>
<td>12:30 p.m.</td>
</tr>
<tr>
<td><strong>Neuropsychology: Longitudinal Cognitive Assessment In Early Stages Of AD</strong>  &lt;br&gt;Sietske Sikkes, Eva Alden, William S. Kremen, Alex C. Birdsill, Bang Zheng, Michael J. Properzi, Mark A. Dubbelman</td>
<td>12:30 p.m.</td>
</tr>
<tr>
<td><strong>Interventions Targeting The Noradrenergic System In Alzheimer’s And Neurodegenerative Disease</strong>  &lt;br&gt;Matthew Betts, Dorothea Hammerer, Heidi I.L. Jacobs, John B. Williamson, James B. Rowe, Qin Wang</td>
<td>1 p.m.</td>
</tr>
<tr>
<td><strong>Clinical Manifestations: Language Markers Of Early Disease</strong>  &lt;br&gt;Jet M.J. Vonk, Kimberly D. Mueller, David G. Clark, David P. Salmon, Miguel Arce Rentería, Seo-Eun Choi</td>
<td>1:30 p.m.</td>
</tr>
<tr>
<td><strong>Results Of The DIAN-TU Prevention Trial Of Solanezumab And Gantenerumab In Dominantly Inherited Alzheimer’s Disease</strong>  &lt;br&gt;Randall J. Bateman, Laurie Ryan, Maria C. Carrillo, Geoffrey Kerchner, Martin Farlow, Stephen Salloway, Roy Yaari</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**THANK YOU TO OUR EXHIBITORS**

Visit the virtual exhibit hall and chat with exhibitors daily from 8-8:30 a.m. and 9:30-10 a.m. Central Daylight Time (North America).

*List as of July 17.*

10x Genomics  
Abbvie  
Abcam  
ACADIA Pharmaceuticals, Inc.  
Active Cues  
Alzheimer’s Association  
Alzheimer’s Clinical Trials Consortium (ACTC)  
Atlantic Fellows for Equity in Brain Health at the Global Brain Health Institute  
Atuka, Inc.  
Bioclinica  
Biocrates Life Sciences AG  
Biogen  
Biomax Informatics AG  
Cogstate  
Combinostics  
CorTechs Labs  
CTAD Congress  
C2N Diagnostics  
Edward Jones  
Eli Lilly & Co.  
Evolution Research Group  
F. Hoffmann-La Roche Ltd.  
Fujirebio Europe  
GE Healthcare  
Glasgow Memory Clinic  
Global Alzheimer’s Association Interactive Network (GAAIN)  
Grifols S.A.  
H. Lundbeck  
HammondCare  
Health and Retirement Study  
IBL America  
icometrix  
Life Molecular Imaging Ltd.  
Mayo Clinic Laboratories  
Merck & Co., Inc.  
National Alzheimer’s Coordinating Center  
National Institute for Health Research  
National Institute of Neurological Disorders and Stroke (NINDS)  
National Institute on Aging  
Neurodiem, a Service from Biogen Inc.  
NeuroScience Associates, Inc.  
Neuroscience Trials Australia  
NIHR Dementia Researcher  
Northwestern University  
Norton Neuroscience Institute  
Optina Diagnostics  
Oskar Fischer Prize - UTSA College of Sciences  
Oxford Health Policy Forum  
PPD  
Proteome Sciences  
QPS  
Quanterix Corporation  
Qynapse  
Recruitment Partners LLC  
Shanghai Green Valley Pharmaceuticals  
Shimadzu Europa GmbH  
Signant Health  
StressMarq Biosciences Inc.  
Sutter Instrument Co  
VeraSci  
Vielight, Inc.

**ATTEND PRODUCT THEATERS**

Learn about exhibitor products, brands and their latest research in on-demand AAIC Product Theaters.

Featured exhibitors include 10x Genomics; Acadia Pharmaceuticals, Inc.; Cogstate; Grifols S.A.; and Quanterix Corporation.
Thank you to the AAIC Scientific Program Committee, comprised of international experts in a variety of topic areas, for their commitment to developing the most relevant and innovative content for the conference.

### Chairs

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philip Scheltens</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Delphine Boche</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

### Committee Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jose F. Abisambra</td>
<td>United States</td>
</tr>
<tr>
<td>Liana Apostolova</td>
<td>United States</td>
</tr>
<tr>
<td>Roxana O. Carare</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Maria M. Corrada</td>
<td>United States</td>
</tr>
<tr>
<td>Sergio Ferreira</td>
<td>Brazil</td>
</tr>
<tr>
<td>Carey Gleason</td>
<td>United States</td>
</tr>
<tr>
<td>Barry Greenberg</td>
<td>United States</td>
</tr>
<tr>
<td>Lea Grinberg</td>
<td>United States</td>
</tr>
<tr>
<td>Rita Guerreiro</td>
<td>United States</td>
</tr>
<tr>
<td>Frank Jessen</td>
<td>Germany</td>
</tr>
<tr>
<td>Kejal Kantarci</td>
<td>United States</td>
</tr>
<tr>
<td>John “Keoni” Kauwe</td>
<td>United States</td>
</tr>
<tr>
<td>Krista Lanctot</td>
<td>Canada</td>
</tr>
<tr>
<td>Nicola Lautenschlager</td>
<td>Australia</td>
</tr>
<tr>
<td>Eddie Lee</td>
<td>United States</td>
</tr>
<tr>
<td>Jose Luis Molinuevo</td>
<td>Spain</td>
</tr>
<tr>
<td>Ozioma Okonkwo</td>
<td>United States</td>
</tr>
<tr>
<td>Niels Prins</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Rema Raman</td>
<td>United States</td>
</tr>
<tr>
<td>Perminder Sachdev</td>
<td>Australia</td>
</tr>
<tr>
<td>Maureen Schmitter-Edgecombe</td>
<td>United States</td>
</tr>
<tr>
<td>Eric Siemers</td>
<td>United States</td>
</tr>
<tr>
<td>Andrea Slachevsky Chonchol</td>
<td>Chile</td>
</tr>
<tr>
<td>Wiesje van der Flier</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Linda Van Eldik</td>
<td>United States</td>
</tr>
</tbody>
</table>

### Ex-Officio Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Dickerson</td>
<td>United States, Immediate Past Chair, Neuroimaging Professional Interest Area</td>
</tr>
<tr>
<td>Cynthia Lemere</td>
<td>United States, Chair, Medical and Scientific Advisory Group</td>
</tr>
<tr>
<td>Jonathan Schott</td>
<td>United Kingdom, Chair, ISTAART Advisory Council</td>
</tr>
</tbody>
</table>
#AAIC20

AWARD RECIPIENTS

**KHALID IQBAL LIFETIME ACHIEVEMENT AWARD IN ALZHEIMER’S RESEARCH**

Christine Van Broeckhoven, M.D., Ph.D.
VIB Center for Molecular Neurology, University of Antwerp, Antwerp, Belgium

**ZAVEN KHACHATURIAN AWARD**

Guy McKhann, M.D.
Johns Hopkins University, Baltimore, Maryland, United States

**BENGT WINBLAD LIFETIME ACHIEVEMENT AWARD IN ALZHEIMER’S RESEARCH**

Francisco Javier Lopera Restrepo, M.D.
University of Antioquia, Medellín, Colombia

**de LEON PRIZE IN NEUROIMAGING**

Senior Scientist - de Leon Prize in Neuroimaging
Prashanthi Vemuri, Ph.D.
Mayo Clinic, Rochester, Minnesota, United States

**HENRY WISNIEWSKI LIFETIME ACHIEVEMENT AWARD IN ALZHEIMER’S RESEARCH**

Steven T. DeKosky, M.D.
Department of Neurology and UF McKnight Brain Institute, University of Florida, Gainesville, Florida, United States

**INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH**

Yakeel T. Quiroz, Ph.D.
Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, United States
View the following on-demand sessions from our corporate sponsors. Sessions will be available beginning on Monday, July 27, at 12 a.m. Content is listed as submitted.

THE EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE: READYING THE HEALTH SYSTEM

Please join our esteemed faculty in this symposium highlighting the importance and practicalities of an early diagnosis in Alzheimer’s disease (AD). With panel discussions throughout, we will explore ways in which cognitive and functional assessments, in addition to pathophysiological biomarkers of AD, may support earlier detection, referral, and diagnosis of AD. As part of this, we will discuss the challenges encompassing an early diagnosis of AD in the context of the current healthcare system and explore possible solutions to overcome these.

We look forward to welcoming you to what promises to be a thought-provoking symposium.

Sponsored by: Biogen and Eisai

THE DEVELOPMENT OF THE A/T/N/X CLASSIFICATION SYSTEM FOR DIFFERENT CONTEXTS OF USE ACROSS THE ALZHEIMER’S DISEASE CONTINUUM: STATE-OF-THE-ART AND FUTURE PERSPECTIVES FOR CLINICAL PRACTICE AND THERAPY DEVELOPMENT

Join Eisai and Biogen for a virtual symposium focusing on the development of the A/T/N/x classification system across the Alzheimer’s disease (AD) continuum. Our expert faculty will provide an overview of the state-of-the-art of the A/T/N/x system and will discuss the main challenges in the validation and qualification process for different contexts of use.

Sponsored by: Eisai and Biogen

EMPOWERING PHYSICIANS TO ADVANCE THE FUTURE OF AD MANAGEMENT AND CARE

This symposium will highlight how improved AD management will be enabled by the response to current societal health challenges, such as the COVID-19 pandemic, as they will transform existing clinical practices. As science and technology advance at unprecedented speed, the symposium will examine the important factors to address to ensure that clinical practice can be optimized in the future and meet the expectations of people with AD and their families.

Sponsored by: Roche

MANAGEMENT CHALLENGES IN DEMENTIA: IMPACT OF PSYCHOSIS ON PATIENT CARE

The management of psychosis in dementia is challenging for clinicians due to limited evidence on clinical efficacy of commonly used antipsychotics. Join Drs. Sabbagh, Ballard and Peskind, who will discuss the pathophysiologic mechanisms of dementia-related psychosis (DRP), its impact on the patient care, how to recognize symptoms and establish a diagnosis of DRP using illustrative case studies and how to set a management plan for patients with DRP with a focus on how to balance risks/benefits of established therapies as well as a review of investigational approaches.

Sponsored by: Acadia Pharmaceuticals

A NEW APPROACH TO ALZHEIMER’S TREATMENT: LEARNINGS FROM THE AMBAR TRIAL

The AMBAR trial is the latest study in Grifols’ Alzheimer’s clinical research program, aimed at assessing whether a medical procedure consisting of plasma exchange and albumin replacement was able to slow the progression of the disease in mild to moderate patients. Join us to see the updated results of the AMBAR study.

Sponsored by: Grifols